Howard Hochster, MD
Medical Oncology · New Haven, CTNPI 1538160668
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $110,715 of the $133,348 with a category attached, or 83.0%. 16 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 38.7% of the total. Reporting peaked in 2024 at $56,490 and has fallen 73.6% since, to $14,914 in 2025.
Across 96 payments — averaging $1389.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$52K
- Merck$13K
- Regeneron$12K
- GSK$11K
- Genentech USA, Inc.$10K
- Bayer$9K
- plus $28K from 10 others
Across 102 payments — averaging $26,488 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.5M
- AstraZeneca$362K
- Daiichi Sankyo Inc.$279K
- Bayer$229K
- Genentech, Inc.$110K
- AbbVie$80K
- plus $100K from 6 others
What the payments were for
- Consulting fees$110,71583%
- Speaking & faculty fees$5,2804%
- Travel & lodging$13,68410%
- Food & beverage$3,6503%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $51,629 |
| Merck | 16 | $13,093 |
| Regeneron | 15 | $11,981 |
| GSK | 5 | $10,813 |
| Genentech USA, Inc. | 12 | $9,547 |
| Bayer | 12 | $8,606 |
| Tempus AI, Inc | 4 | $6,940 |
| Taiho Oncology, Inc. | 2 | $6,650 |
| Exelixis Inc. | 7 | $6,121 |
| Eisai Inc. | 1 | $2,280 |
| Beigene USA, Inc. | 1 | $2,250 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,845 |
| Roche Products Limited | 1 | $990 |
| Genentech, Inc. | 3 | $334 |
| Astrazeneca UK Limited | 1 | $135 |
| AstraZeneca | 1 | $135 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,348 in reported general payments places this provider in the 85th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 28 | $311 |
| Ondansetron Hcl | 41 | $266 |
| Pantoprazole Sodium | 13 | $64 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Haven
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Francine FossNew Haven$193K
- Anne ChiangNew Haven$158K
- Mario SznolNew Haven$157K
- Lajos PusztaiNew Haven$152K
- Sarah GoldbergNew Haven$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.